Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

Anne L. Taylor*, Susan Ziesche, Clyde Yancy, Peter Carson, Ralph D'Agostino, Keith Ferdinand, Malcolm Taylor, Kirkwood Adams, Michael Sabolinski, Manuel Worcel, Jay N. Conn

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1233 Scopus citations

Abstract

BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1±1.9 vs. -0.5±2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6±20.6 vs. -2.7±21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.

Original languageEnglish (US)
Pages (from-to)2049-2057+2141
JournalNew England Journal of Medicine
Volume351
Issue number20
DOIs
StatePublished - Nov 11 2004

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Combination of isosorbide dinitrate and hydralazine in blacks with heart failure'. Together they form a unique fingerprint.

Cite this